Trials / Terminated
TerminatedNCT04974970
Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- University Hospital, Geneva · Academic / Other
- Sex
- All
- Age
- 12 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to assess the safety and efficacy of peanut immunotherapy in children and adults with peanut allergy. Participants will receive immunotherapy with peanut every 2 weeks for a period of 3 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peanut Immunotherapy | Treatment will be injected peanut extract every 2 weeks for a period of 3 months. |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2022-04-19
- Completion
- 2022-04-19
- First posted
- 2021-07-23
- Last updated
- 2023-08-28
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT04974970. Inclusion in this directory is not an endorsement.